Literature DB >> 29683859

Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.

Tímea Sebestyén1, Anita Mohos2, Gabriella Liszkay3, Beáta Somlai4, István Gaudi5, Andrea Ladányi6.   

Abstract

High endothelial venules (HEVs) are specialized vessels in lymphoid organs, supporting lymphocyte trafficking from the blood. As the presence of these vessels was described recently in tumors, it was proposed that they could facilitate the development of antitumor immune response, resulting in improved prognosis. The aim of our study was to analyze the correlation of the density of HEVs with that of the different immune cell types as well as with the clinicopathologic parameters and the disease outcomes in patients with cutaneous melanoma. Primary melanoma samples of 118 patients were analyzed retrospectively by immunohistochemical labeling and quantitation of vessels stained with the MECA-79 antibody, as well as a panel of eight different immune cell types (CD8 and CD45RO T cells, lymphocytes expressing the CD25, CD134, or CD137 activation markers, FOXP3 regulatory T cells, CD20 B cells, and DC-LAMP mature dendritic cells). Correlations of MECA-79 vessel density with that of the immune cells, as well as with clinicopathologic parameters and disease outcomes were evaluated. We showed that the number of MECA-79 vessels correlates strongly with the peritumoral density of B and T lymphocytes. Moreover, higher HEV numbers were detected in tumors hosting tertiary lymphoid structures as well as in those of axial location compared with the ones in the extremity and in men compared with women, whereas no association was found with patient age, tumor thickness, histologic type or ulceration, or with the survival of melanoma patients. The density of MECA-79 HEVs in primary melanomas shows a correlation with B and T-lymphocyte density and differences according to the presence of tertiary lymphoid structures, tumor site, and the sex of the patient. However, it has no prognostic value.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29683859     DOI: 10.1097/CMR.0000000000000457

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

Review 1.  B cells and antibody production in melanoma.

Authors:  Jessica Da Gama Duarte; Janique M Peyper; Jonathan M Blackburn
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

2.  The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.

Authors:  Satu Salmi; Anton Lin; Benjamin Hirschovits-Gerz; Mari Valkonen; Niina Aaltonen; Reijo Sironen; Hanna Siiskonen; Sanna Pasonen-Seppänen
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

3.  Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

Authors:  João Lobo; Ad J M Gillis; Annette van den Berg; Leendert H J Looijenga
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

Review 4.  High endothelial venules (HEVs) in immunity, inflammation and cancer.

Authors:  Lucas Blanchard; Jean-Philippe Girard
Journal:  Angiogenesis       Date:  2021-05-06       Impact factor: 9.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.